Literature DB >> 25928701

Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.

Mark A Frye1, Pierre Blier, Susannah J Tye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25928701     DOI： 10.1097/JCP.0000000000000316

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  13 in total

1.  Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Authors:  William V Bobo; Patricio Riva-Posse; Fernando S Goes; Sagar V Parikh
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

2.  Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.

Authors:  Samuel T Wilkinson; Rachel B Katz; Mesut Toprak; Ryan Webler; Robert B Ostroff; Gerard Sanacora
Journal:  J Clin Psychiatry       Date:  2018-07-24       Impact factor: 4.384

Review 3.  Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain.

Authors:  Álvaro López-Díaz; José Luis Fernández-González; José Evaristo Luján-Jiménez; Sara Galiano-Rus; Luis Gutiérrez-Rojas
Journal:  Ther Adv Psychopharmacol       Date:  2017-01-01

Review 4.  Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability.

Authors:  Michael D Kritzer; Chi-Un Pae; Prakash S Masand
Journal:  Expert Opin Drug Saf       Date:  2022-04-29       Impact factor: 4.011

5.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.

Authors:  Jennifer Swainson; Alexander McGirr; Pierre Blier; Elisa Brietzke; Stéphane Richard-Devantoy; Nisha Ravindran; Jean Blier; Serge Beaulieu; Benicio N Frey; Sidney H Kennedy; Roger S McIntyre; Roumen V Milev; Sagar V Parikh; Ayal Schaffer; Valerie H Taylor; Valérie Tourjman; Michael van Ameringen; Lakshmi N Yatham; Arun V Ravindran; Raymond W Lam
Journal:  Can J Psychiatry       Date:  2020-11-11       Impact factor: 4.356

Review 6.  Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action.

Authors:  Madison N Irwin; Amy VandenBerg
Journal:  Ment Health Clin       Date:  2021-05-12

Review 7.  Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer.

Authors:  Sagar V Parikh; Daniela Lopez; Jennifer L Vande Voort; Jose Rico; Eric Achtyes; William Coryell; Andrew Goddard; Fernando Goes; John F Greden; Balwinder Singh; Adam Kaplin; Mark A Frye; Daniel Maixner; Brendon Watson; Karina Drake; Vijay Tarnal; Patricio Riva-Posse; William V Bobo
Journal:  Psychopharmacol Bull       Date:  2021-06-01

8.  Ketamine: stimulating antidepressant treatment?

Authors:  Gin S Malhi; Yulisha Byrow; Frederick Cassidy; Andrea Cipriani; Koen Demyttenaere; Mark A Frye; Michael Gitlin; Sidney H Kennedy; Terence A Ketter; Raymond W Lam; Rupert McShane; Alex J Mitchell; Michael J Ostacher; Sakina J Rizvi; Michael E Thase; Mauricio Tohen
Journal:  BJPsych Open       Date:  2016-05-11

Review 9.  Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.

Authors:  Brittany A Jaso; Mark J Niciu; Nicolas D Iadarola; Niall Lally; Erica M Richards; Minkyung Park; Elizabeth D Ballard; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

10.  Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials.

Authors:  Bettina Diekamp; Stephane Borentain; Dong-Jing Fu; Robert Murray; Kristin Heerlein; Qiaoyi Zhang; Cornelius Schüle; Maju Mathews
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-15       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.